Although Trastuzumab, both as a monotherapy and combined with other agents, has not proven effective in HNSCC, no trials have yet explored the use of anti‐HER2 ADCs, such as T‐DM1 or T‐DXd, in this context. Here, ERBB2 is linked to head and neck squamous cell carcinoma.